Interferon-α/β Receptor as a Prognostic Marker in Osteosarcoma

Interferon-alpha/beta Receptor as a Prognostic Marker in Osteosarcoma

Kubo Tadahiko

Shimose Shoji

Matsuo Toshihiro

Fujimori Jun

Arihiro Koji

Ochi Mitsuo

The Journal of bone and joint surgery. American volume

Background: A large-scale randomized trial of adjuvant interferon-a therapy for patients with osteosarcoma has been initiated as a joint protocol by the European and American Osteosarcoma Study Group. Because the expression of functional interferon-α/β receptor is necessary for interferon-a agents to interact with osteosarcoma cells, we examined the expression of interferon-α/β receptor in a series of osteosarcoma specimens.

Methods: Forty patients with high-grade resectable osteosarcoma, from whom surgical specimens had been obtained at the time of biopsy, were included in this retrospective study. Biopsy specimens were immunohistochemically stained with anti-interferon-α/β receptor antibodies. Survival was estimated with the Kaplan-Meier method. The Cox proportional hazards model was used for multivariate analysis to determine the independent prognostic factors. Furthermore, we used Holm and Benjamini-Hochberg procedures to adjust for multiple comparisons in setting the level of significance. The median follow-up period was five years and two months (range, four to 195 months).

Results: The expression of interferon-α/β receptor was positive in eighteen (45%) of the forty patients with high-grade osteosarcoma. American Joint Committee on Cancer surgical stage IIA, a good histologic response to chemotherapy, and expression of interferon-α/β receptor correlated significantly with better disease-free survival (p < 0.05). Multivariate analysis showed that interferon-α/β receptor expression alone retained its power to predict an improved prognosis (p = 0.042). There were no significant variables after corrections for multiple comparisons.

Conclusions: Interferon-α/β receptor may be a useful marker for assessing tumor prognosis in patients with osteosarcoma and may play an important role in tumor progression. These findings are encouraging and support the ongoing clinical trials of adjuvant interferon-a therapy by the multinational Osteosarcoma Study Group. Our pilot study was based on a small sample size, and larger trials are needed to confirm this finding.

Level of Evidence: Prognostic Level II. See Instructions to Authors for a complete description of levels of evidence.

Medical sciences [ 490 ]

eng

The Journal of Bone and Joint Surgery

Copyright (c) 2011 The Journal of Bone and Joint Surgery

[ISSN] 0021-9355

[DOI] 10.2106/JBJS.J.00198

[NCID] AA00694335

[DOI] http://dx.doi.org/10.2106/JBJS.J.00198